HB 112-PROFESSION OF PHARMACY  3:18:07 PM CHAIR SUMNER announced that the first order of business would be HB 112, "An Act relating to the Board of Pharmacy; relating to the practice of pharmacy; relating to pharmacies; relating to prescription drug manufacturers; relating to prescriptions for epinephrine; relating to the administration of epinephrine; and providing for an effective date." 3:18:29 PM REPRESENTATIVE RUFFRIDGE, as prime sponsor, stated that HB 112 is part of a multi-year process and has the support of the Board of Pharmacy. 3:19:15 PM The committee took a brief at-ease. 3:19:53 PM REPRESENTATIVE PRAX moved to adopt Amendment 1 to HB 112, labeled, 33-LS0600\A.1, Bergerud, 4/13/23, which read as follows: Page 1, line 2, following "manufacturers;": Insert "relating to licensing and registration  requirements for certain wholesale drug distributors;" Page 4, following line 11: Insert a new bill section to read:  "* Sec. 4. AS 08.80.157(h) is amended to read: (h) The board may suspend, revoke, deny, or refuse to renew the license of a facility or pharmacy on the following grounds: (1) the finding by the board of violations of a federal, state, or local law relating to the practice of pharmacy, drug samples, wholesale or retail drug or device distribution, or distribution of controlled substances; (2) a felony conviction under federal, state, or local law of an owner of the facility or pharmacy or of an employee of the facility or pharmacy; (3) the furnishing of false or fraudulent material in an application made in connection with drug or device manufacturing or distribution; (4) suspension or revocation by federal, state, or local government of a license currently or previously held by the applicant for the manufacture or distribution of drugs or devices, including controlled substances; (5) obtaining remuneration by fraud, misrepresentation, or deception; (6) dealing with drugs or devices that are known or should have been known to be stolen drugs or devices; (7) dispensing or distributing drugs or devices directly to patients by a wholesale drug distributor other than a pharmacy unless (A) the drug or device is a dialysate, drug  composed solely of fluids, electrolytes, and sugars,  or device that is  (i) necessary to perform home dialysis;  (ii) approved by the United States Food and  Drug Administration, as required by federal law; and  (iii) delivered in its original, sealed,  and labeled packaging only upon the receipt of a  physician's order; and  (B) the wholesale drug distributor (i) delivers the dialysate drug or device  directly to a patient with end-stage renal disease, or  to the patient's designee, for the patient's self- administration of dialysis therapy;  (ii) uses a bar code scanning and  verification system confirming that the dialysate drug  or device selected to fill the patient-specific order  matches the information on the patient-specific label;  and  (iii) has additional secondary accuracy and  delivery checks in place; and  (C) a licensed pharmacist serves as a  consultant to the wholesale drug distributor to  (i) conduct a retrospective audit of 10  percent of the dialysate drug and device orders  provided directly to patients processed by the  wholesale drug distributor every month; and  (ii) perform assessments at least twice  monthly to ensure quality of product storage,  handling, and distribution by the wholesale drug  distributor, and to ensure product expiration dates  are later than three months after the date of  assessment;  (8) violation of this chapter or a regulation adopted under this chapter." Renumber the following bill sections accordingly. Page 9, line 20: Delete "sec. 18" Insert "sec. 19" Page 9, line 21: Delete "sec. 18" Insert "sec. 19" Page 9, line 31: Delete "Section 20" Insert "Section 21" Page 9, following line 31: Insert a new bill section to read: "* Sec. 23. Section 4 of this Act takes effect May 7, 2023." Renumber the following bill section accordingly. Page 10, line 1: Delete "sec. 21" Insert "secs. 22 and 23" REPRESENTATIVE RUFFRIDGE objected for the purpose of discussion. 3:20:26 PM REPRESENTATIVE PRAX explained that Amendment 1 would enable home dialysis distributors to do so directly with the patient. 3:21:48 PM REPRESENTATIVE RUFFRIDGE removed his objection to Amendment 1. There being no further objection, Amendment 1 was adopted. 3:22:11 PM REPRESENTATIVE RUFFRIDGE moved to report HB 112, as amended, out of committee with individual recommendations and the accompanying fiscal notes. There being no objection, CSHB 112(L&C) was reported from the House Labor and Commerce Standing Committee.